The unbound portion of Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT). Use of ferric citrate in patients with IDA, NDD-CKD, as highlighted above, is investigational and has not been determined to be safe or efficacious. Iron parameters should be monitored prior to and while on Auryxia.Iron absorption from Auryxia may lead to excessive elevations in iron stores. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.“This demand was largely driven by solid execution across our entire field team, which increased both breadth and depth of prescribing among physicians.With this momentum, we have increased our annual net Auryxia product sales guidance, reflecting improved confidence in our ability to bring this medicine to a greater number of people with chronic kidney disease (CKD) on dialysis this year.” Mr.Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age.The most common adverse events for Auryxia treated patients were gastrointestinal related, including diarrhea, nausea, vomiting and constipation. Keep Auryxia away from children as it contains iron.“Additionally, the capital raised via the ATM strengthens our balance sheet and provides us with the financial flexibility to continue to appropriately invest in our business to support our anticipated growth.” Total revenues for the quarter ended June 30, 2017 were .1 million, compared with .3 million during the same period in 2016.Total revenues for the second quarter of 2017 include .1 million in net U. Auryxia product sales, compared to .3 million in the second quarter of 2016.
The increase was related to the continued commercialization of Auryxia, and preparations for Auryxia’s potential launch in iron deficiency anemia later this year.
Research and development expenses for the quarter ended June 30, 2017 were .0 million, as compared to .0 million during the same period in 2016.
The increase was primarily related to manufacturing and clinical activities to support the long-term growth of Auryxia.
Today, there are no FDA approved oral irons for the treatment of IDA in CKD patients and the efficacy and tolerability of current oral iron supplements are mixed.
The company estimates that of the 1.7 million Americans with CKD under the care of a nephrologist, approximately 650,000 people are treated for IDA and another 250,000 – 400,000 people could have IDA but are not treated today. approval of Auryxia was based on data from the company's Phase 3 registration program in dialysis patients.